GTS Securities’s FibroBiologics FBLG Stock Holding History

GTS Securities’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,433	Closed	-$169K	–	1853
2025 Q3	$169K	Buy	+15,433	New	+$185K	0.01%	1320

Other funds holding FBLG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

ANTB

AMG National Trust Bank Greenwood Village, Colorado $4.88B AUM 24.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GTS Securities's FBLG Position: Q4 2025 in Review

GTS Securities sold out of FibroBiologics (FBLG) in Q4 2025, closing a stake of 15,433 shares — an estimated $169K sold.

GTS Securities first reported a position in FBLG in Q3 2025 and held it in 1 quarter. The position peaked at $169K in Q3 2025. 45 funds tracked by Wall St. Rank hold FBLG as of Q4 2025.

GTS Securities reported no remaining FibroBiologics position as of Q4 2025 after selling out during the quarter.
GTS Securities sold 15,433 FibroBiologics shares in Q4 2025, an estimated $169K.
GTS Securities first reported a position in FibroBiologics in Q3 2025 and held it in 1 quarter.
GTS Securities's FibroBiologics position peaked at $169K in Q3 2025.
45 funds tracked by Wall St. Rank held FibroBiologics as of Q4 2025.

Based on GTS Securities's 13F filing for Q4 2025, filed 13 Feb 2026.